Although new treatments have been widely studied to improve the survival of patients with metastatic breast cancer (BC), prognosis continues to be poor with an average survival time no longer than 3 years. We carried on a population-based study with the purpose of evaluating the outcome of metastatic breast cancer in the province of Modena from 1990 to 2009. We examined the Modena Cancer Registry and evaluated the 5-year overall survival (OS) of women diagnosed with a de novo metastatic breast cancer between 1990 and 2009, defining 5 periods of 4 years each. After a median follow-up time of 29 months, the 5-year OS was 11% for years 1990-1993, 15% for years 1994-1997, 12% for years 1998-2001, 20% for years 2002-2005 and 29% for years 2006-2009 (p = 0.012). Overall, although no OS differences were noted in the first decade analyzed, a real advantage has been shown in the last two cohorts. In a multivariate analysis, the 5-year OS was significantly increased only for hormone receptor positive and HER2+ tumors, whereas chemotherapy treatments were not significant independent predictors of survival in "de novo" metastatic BC (p = 0.08). Our analysis confirms that the prognosis of de novo metastatic breast cancer has improved overtime, particularly in the last decade. Trastuzumab, LH-RH analogues and aromatase inhibitors have determined a significant clinical benefit and cost-effectiveness in metastatic breast cancer treatment.

Twenty-years experience with de novo metastatic breast cancer / Cortesi, Laura; Toss, Angela; Cirilli, Claudia; Marcheselli, Luigi; Braghiroli, Barbara; Sebastiani, Federica; Federico, Massimo. - In: INTERNATIONAL JOURNAL OF CANCER. - ISSN 0020-7136. - STAMPA. - 137:6(2015), pp. 1417-1426. [10.1002/ijc.29503]

Twenty-years experience with de novo metastatic breast cancer

TOSS, ANGELA;MARCHESELLI, Luigi;SEBASTIANI, FEDERICA;FEDERICO, Massimo
2015

Abstract

Although new treatments have been widely studied to improve the survival of patients with metastatic breast cancer (BC), prognosis continues to be poor with an average survival time no longer than 3 years. We carried on a population-based study with the purpose of evaluating the outcome of metastatic breast cancer in the province of Modena from 1990 to 2009. We examined the Modena Cancer Registry and evaluated the 5-year overall survival (OS) of women diagnosed with a de novo metastatic breast cancer between 1990 and 2009, defining 5 periods of 4 years each. After a median follow-up time of 29 months, the 5-year OS was 11% for years 1990-1993, 15% for years 1994-1997, 12% for years 1998-2001, 20% for years 2002-2005 and 29% for years 2006-2009 (p = 0.012). Overall, although no OS differences were noted in the first decade analyzed, a real advantage has been shown in the last two cohorts. In a multivariate analysis, the 5-year OS was significantly increased only for hormone receptor positive and HER2+ tumors, whereas chemotherapy treatments were not significant independent predictors of survival in "de novo" metastatic BC (p = 0.08). Our analysis confirms that the prognosis of de novo metastatic breast cancer has improved overtime, particularly in the last decade. Trastuzumab, LH-RH analogues and aromatase inhibitors have determined a significant clinical benefit and cost-effectiveness in metastatic breast cancer treatment.
2015
23-mar-2015
137
6
1417
1426
Twenty-years experience with de novo metastatic breast cancer / Cortesi, Laura; Toss, Angela; Cirilli, Claudia; Marcheselli, Luigi; Braghiroli, Barbara; Sebastiani, Federica; Federico, Massimo. - In: INTERNATIONAL JOURNAL OF CANCER. - ISSN 0020-7136. - STAMPA. - 137:6(2015), pp. 1417-1426. [10.1002/ijc.29503]
Cortesi, Laura; Toss, Angela; Cirilli, Claudia; Marcheselli, Luigi; Braghiroli, Barbara; Sebastiani, Federica; Federico, Massimo
File in questo prodotto:
File Dimensione Formato  
408 (ex745).pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 297.87 kB
Formato Adobe PDF
297.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1065932
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 28
social impact